IFNA1 and type 1 diabetes mellitus: Moreover, although the data do not prove that active anti-IFN antibodies underpin selective protection from T1D, they provide a firm foundation for exploring the potentials of APS1/APECED-derived autoantibodies to ameliorate other major diseases that are rarely if ever present in APS1/APECED patients.